MRNA · News · 20260731N
Product / Drug Pipeline Progress
Moderna, Inc. · 2026-07-31 · Importance 40 · Surprise 42 · In source text
Moderna’s mRNA-1403 norovirus vaccine candidate did not meet the statistical criteria for early success in a Phase 3 interim analysis. The blinded study remains ongoing, and Moderna is preparing to enroll an additional cohort to evaluate efficacy during the winter season. The setback increases execution risk for the company’s effort to offset declining COVID-19 vaccine demand with respiratory, oncology, and rare-disease programs.
Key facts
- Moderna announced that mRNA-1403, its norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis and the company is preparing to enroll an additional cohort. source
- Bloomberg reported Moderna will recruit more patients to evaluate the seasonal shot's effectiveness this winter after the norovirus Phase 3 interim analysis failure. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | Moderna announced that mRNA-1403, its norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3… |